Αρχική World News Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus... World News Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma Από Ogkologos - 10 Ιουνίου, 2025 921 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene Alterations 15 Ιουνίου, 2020 News digest – skin cancer deaths, Public Health England plans and... 22 Αυγούστου, 2020 Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment... 2 Αυγούστου, 2023 Doctor Wipes Away The Debt Of 200 Cancer Patients 6 Ιανουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS 3 Steps to Making the Right Decisions for You During Cancer:... PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows Can Cancer Symptoms Be Mistaken for Menopause? Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has...